Liver transplant recipients have an increased risk of developing colorectal adenomas: Results from a retrospective study.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
01 2021
Historique:
received: 11 06 2020
revised: 27 10 2020
accepted: 07 11 2020
pubmed: 16 11 2020
medline: 24 6 2021
entrez: 15 11 2020
Statut: ppublish

Résumé

Liver transplant recipients have an increased incidence of malignancies, but it is unclear whether they have a higher risk of colorectal cancer. To investigate whether liver transplant recipients have an increased risk of developing colorectal adenomas (a surrogate marker of colorectal cancer risk). One hundred thirty-nine liver transplant recipients (excluding primary sclerosing cholangitis) who underwent a colonoscopy and polypectomy before and after transplantation, and 367 nontransplanted patients who underwent a colonoscopy for colorectal cancer screening and a second colonoscopy later were retrospectively studied. The risks of incident colorectal adenomas and high-risk adenomas (advanced or multiple adenomas or carcinomas) were compared between both cohorts. Incident colorectal adenomas were found in 40.3% of the transplanted patients and 30.0% of the nontransplanted patients (15.1% and 5.5%, respectively, had high-risk adenomas). After adjusting for age, sex, presence of adenomas in the baseline endoscopy, and interval between colonoscopies, transplant recipients showed a higher risk of developing colorectal adenomas (OR: 1.61; 95% CI: 1.05-2.47; p = .03) and high-risk adenomas (OR: 2.87; 95% CI: 1.46-5.65; p = .002). Our results suggest that liver transplant recipients have an increased risk of developing colorectal adenomas and lesions with high risk of colorectal cancer.

Sections du résumé

BACKGROUND
Liver transplant recipients have an increased incidence of malignancies, but it is unclear whether they have a higher risk of colorectal cancer.
AIM
To investigate whether liver transplant recipients have an increased risk of developing colorectal adenomas (a surrogate marker of colorectal cancer risk).
PATIENTS AND METHODS
One hundred thirty-nine liver transplant recipients (excluding primary sclerosing cholangitis) who underwent a colonoscopy and polypectomy before and after transplantation, and 367 nontransplanted patients who underwent a colonoscopy for colorectal cancer screening and a second colonoscopy later were retrospectively studied. The risks of incident colorectal adenomas and high-risk adenomas (advanced or multiple adenomas or carcinomas) were compared between both cohorts.
RESULTS
Incident colorectal adenomas were found in 40.3% of the transplanted patients and 30.0% of the nontransplanted patients (15.1% and 5.5%, respectively, had high-risk adenomas). After adjusting for age, sex, presence of adenomas in the baseline endoscopy, and interval between colonoscopies, transplant recipients showed a higher risk of developing colorectal adenomas (OR: 1.61; 95% CI: 1.05-2.47; p = .03) and high-risk adenomas (OR: 2.87; 95% CI: 1.46-5.65; p = .002).
CONCLUSIONS
Our results suggest that liver transplant recipients have an increased risk of developing colorectal adenomas and lesions with high risk of colorectal cancer.

Identifiants

pubmed: 33190329
doi: 10.1111/ctr.14154
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14154

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15(Suppl 2):S90-S94.
Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant setting. Liver Transpl. 2012;18:12771289.
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891-1901.
Boonstra K, Weersma RK, Van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045-2055.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48-54.
Rossi RE, Conte D, Massironi S. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol. 2016;28:123-131.
Karlsen TH, Folseraas T, Thornurn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1293-1323.
Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 2017;86:93-104.
Sint Nicolaas J, de Jonge V, Steyerberg EW, Kuipers EJ, van Leerdam ME, Veldzuyzen-van Zanten SJO. Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am J Transplant. 2010;10:868-876.
Séreé O, Altieri M, Guillaume E, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study of 11,226 patients. Liver Transpl. 2018;24:1425-1436.
Rompiaseni G, Ravikumar R, Jose S, et al. Incidence and outcome of colorectal cancer in liver transplant recipients: a national multicentre analysis on 8115 patients. Liver Int. 2019;39:353-360.
Betés M, Muñoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003;98:2648-2654.
Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multisociety Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844-857.
Aronchick CA, Lipshutz WH, Wright SH, DuFrayne F, Bergman G. Validation of an instrument to assess colon cleansing (abstract). Am J Gastroenterol. 1999;94:2667.
Herrero JI, Alegre F, Quiroga J, et al. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant. 2009;23:532-536.
Rosner B. Fundamentals of biostatistics, 8th edn. Boston: Cengage Learning; 2015.
Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression, 3rd edn. Hoboken: John Wiley & Sons; 2013.
Corley DA, Jensen CD, Marks AM, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370:1298-1306.
Løberg M, Kalager M, Holme Ø, Hoff G, Adami H-O, Bretthauer M. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med. 2014;371:799-807.
Click B, Piusky PF, Hickey T, Dorondi M, Schoen RE. Association of colonoscopy adenoma findings with long-term colorectal cancer incidence. JAMA. 2018;319:2021-2031.
Wong G, Hope RL, Howard K, et al. One-time fecal immunochemical screening for advanced colorectal neoplasia in patients with CKD (DETECT Study). JASN. 2019;30:1061-1072.
Zhu JZ, Wang YM, Zhou QY, Zhu KF, Yu CH, Li YM. Systematic review and meta-analysis: alcohol consumption and the risk of colorectal adenoma. Aliment Pharmacol Ther. 2014;40:325-337.
Cai S, Li Y, Ding Y, Chen K, Jin M. Alcohol drinking and the risk of colorectal cancer death: a meta-analysis. Eur J Cancer Prev. 2014;23:532-539.
Atassi T, Thuluvat PJ. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol. 2003;37:72-73.
Lee H-S, Yoo D-J, Park HW, et al. Is a stricter colonoscopy screening protocol necessary in liver transplant recipients? Comparison with average-risk population. Dis Colon Rectum. 2014;57:976-982.
Robertson DJ, Ladabaum U. Opportunities and challenges in moving from current guidelines to personalized colorectal cancer screening. Gastroenterology. 2019;156:904-917.
D’Arcy ME, Coghill AE, Lynch CF, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;156:933-942.
Finkenstedt A, Graziadei IW, Oberaigner V, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancy in liver transplant recipients. Am J Transplant. 2009;9:2355-2361.
Herrero JI, Bastarrika G, D’Avola D, et al. Lung cancer screening with low-radiation dose computed tomography after liver transplantation. Ann Transplant. 2013;18:587-592.
Acuna SA, Huang JW, Scott AL, et al. Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. Am J Transplant. 2017;17:103-114.
Oey RC, van Tilburg L, Erler NS, et al. The yield and safety of screening colonoscopy in patients evaluated for liver transplantation. Hepatology. 2019;69:2598-2667.

Auteurs

José Ignacio Herrero (JI)

Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain.
Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Marta Quiñones (M)

Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain.

Xabier Pérez (X)

Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain.

Lorena Mora (L)

Servicio de Digestivo, Hospital Santiago Apóstol, Miranda de Ebro, Spain.

Alejandro Bojórquez (A)

Servicio de Digestivo, Clínica Universidad de Navarra, Pamplona, Spain.

Estefanía Toledo (E)

Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Department of Preventive Medicine and Public Health, Universidad de Navarra School of Medicine, Pamplona, Spain.
Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutricion (CIBERobn), Madrid, Spain.

Maite Betés (M)

Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Servicio de Digestivo, Clínica Universidad de Navarra, Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH